Prenatal Genetic Testing: Screening vs. Diagnostic Procedures

How Genetic Disorders Are Detected Before Birth

Prenatal genetic testing falls into two categories: screening (risk estimation, non-invasive) and diagnostic (definitive diagnosis, invasive). Understanding the difference is crucial for informed decision-making.

1. Prenatal Screening (Risk Assessment Only)

Cannot diagnose; only identifies increased probability. No miscarriage risk.

  • First-Trimester Combined Screen (11-14 wks): Nuchal translucency ultrasound + maternal blood (PAPP-A, hCG). Screens for Trisomy 21, 18, 13. Detection ~85-90%, false positive ~5%.
  • Second-Trimester Quad Screen (15-22 wks): Maternal blood (AFP, hCG, estriol, inhibin-A). Adds neural tube defect screening. Detection ~80% for T21.
  • Cell-Free DNA / NIPT (from 10 wks): Analyzes placental DNA in maternal blood. Highest sensitivity (>99% for T21, T18, T13), low false positive (<0.1%). Also screens sex chromosomes, microdeletions. Not diagnostic—high-risk result requires confirmation.
  • Anatomy Ultrasound (18-22 wks): Structural survey. Detects physical markers (heart defects, brain anomalies, limb differences) suggestive of genetic syndromes.

2. Prenatal Diagnostic Testing (Definitive Diagnosis)

Analyzes fetal chromosomes/DNA directly. Carries small miscarriage risk (~0.1-0.3%).

  • Chorionic Villus Sampling (CVS) — 10-13 wks: Catheter/needle samples placental villi (same DNA as fetus). Earliest diagnosis. Cannot detect neural tube defects. Risk: ~0.2% miscarriage; rare limb defects if <10 wks.
  • Amniocentesis — 15-20+ wks: Needle samples amniotic fluid (fetal skin cells). Gold standard. Detects chromosomes, DNA mutations, neural tube defects (AFP), infections, lung maturity. Risk: ~0.1-0.3% miscarriage.
  • Preimplantation Genetic Testing (PGT) — IVF Only: Biopsy of embryo (day 5-6 blastocyst) before transfer.
    • PGT-A: Aneuploidy (chromosome count)
    • PGT-M: Monogenic disorders (cystic fibrosis, Tay-Sachs, etc.)
    • PGT-SR: Structural rearrangements (translocations)

Decision Framework

  1. Screen First (NIPT + Anatomy US): Most patients. Low risk, high info.
  2. Diagnostic If: High-risk screen, ultrasound anomalies, known carrier status, advanced maternal age (35+) wanting certainty, prior affected pregnancy.
  3. CVS vs. Amnio: CVS earlier (decision time); Amnio includes neural tube + lower limb risk.

Critical Counseling Points

  • Positive screen ≠ affected baby. PPV depends on prevalence (e.g., NIPT T21 PPV ~33% at age 25, ~90% at 40).
  • Diagnostic tests detect what they're designed for. Standard karyotype misses single-gene disorders; microarray adds CNVs; exome sequencing adds point mutations (ordered selectively).
  • Non-directive counseling is standard. Providers give facts; you decide based on values.

Next Step: Discuss with your OB/MFM or genetic counselor. They tailor the plan to your history, ethnicity, and preferences.

  • Your child will probably become interested in standing between the ages of 6 and 9 months. Standing gives children access to a whole new world -- for better and for worse. Whether your little one is just starting to stand or needs some more practice
  • High white shoes with hard soles -- the kind your grandparents might have had bronzed -- are best left decorating bookends. Todays babies wear shoes with soft, flexible soles for a good reason: theyre better for your babys feet. If grandma wants to k
  • Depth perception refers to the ability to see and understand the 3-D spatial relationship and relative distance between objects and oneself. Its primary value is to make hand-eye coordination efficient and provide for safe movement through space. Inf